REGENXBIO Inc. (NASDAQ:RGNX) Shares Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC boosted its position in REGENXBIO Inc. (NASDAQ:RGNX) by 630.9% during the second quarter, Holdings Channel.com reports. The fund owned 146,259 shares of the biotechnology company’s stock after purchasing an additional 126,249 shares during the quarter. Squarepoint Ops LLC’s holdings in REGENXBIO were worth $1,711,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in RGNX. PNC Financial Services Group Inc. raised its holdings in shares of REGENXBIO by 73.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 746 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in REGENXBIO in the first quarter valued at approximately $56,000. Headlands Technologies LLC raised its holdings in REGENXBIO by 276.8% in the first quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock valued at $81,000 after buying an additional 2,812 shares during the period. Diversified Trust Co acquired a new position in REGENXBIO during the second quarter valued at approximately $121,000. Finally, Arizona State Retirement System grew its stake in REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after buying an additional 1,997 shares during the period. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Stock Up 4.0 %

Shares of NASDAQ RGNX opened at $9.72 on Friday. REGENXBIO Inc. has a fifty-two week low of $9.29 and a fifty-two week high of $28.80. The business has a 50 day moving average price of $11.94 and a two-hundred day moving average price of $14.21. The firm has a market cap of $478.77 million, a PE ratio of -1.65 and a beta of 1.21.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.24. The business had revenue of $22.30 million during the quarter, compared to the consensus estimate of $22.97 million. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned ($1.66) earnings per share. On average, analysts anticipate that REGENXBIO Inc. will post -4.66 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Curran Simpson sold 9,648 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $15.04, for a total value of $145,105.92. Following the sale, the chief executive officer now owns 170,137 shares in the company, valued at approximately $2,558,860.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Kenneth T. Mills sold 12,221 shares of the firm’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $13.78, for a total transaction of $168,405.38. Following the transaction, the director now directly owns 408,035 shares in the company, valued at $5,622,722.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Curran Simpson sold 9,648 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $15.04, for a total transaction of $145,105.92. Following the sale, the chief executive officer now owns 170,137 shares of the company’s stock, valued at approximately $2,558,860.48. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 65,279 shares of company stock valued at $864,034 in the last ninety days. Corporate insiders own 13.13% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Barclays cut their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. The Goldman Sachs Group assumed coverage on REGENXBIO in a research report on Friday, June 7th. They issued a “buy” rating and a $38.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $39.00 target price on shares of REGENXBIO in a report on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, REGENXBIO has an average rating of “Moderate Buy” and an average price target of $37.91.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.